| Parameter | Saxenda (Liraglutide 3 mg) | Retatrutide (Phase 2, 12 mg) | |-----------|--------------------------|------------------------------| | Titration duration | 5 weeks | ~24 weeks | | Dosing frequency | Daily | Weekly | | Mean weight loss | 8.0% at 56 weeks | 24.2% at 48 weeks | | Nausea (any grade) | 39.3% | 45% | | Vomiting (any grade) | 15.7% | 25% | | Diarrhea (any grade) | 20.9% | 22% | | GI-related discontinuation | ~9.8% | ~6% | | Heart-rate increase (mean) | ~2 to 3 bpm | ~4 bpm | | FDA approval status | Approved (2014) | Not yet approved | | Injection frequency | Daily | Weekly | Sources: SCALE 2015 [14], Jastreboff 2023 [15]
Through these mechanisms, Denmark researchers believe that Epithalon can contribute to improved cellular health, potentially slowing down the aging process and promoting longevity
A personalized approach to weight loss Remembering that weight loss is not a one-size-fits-all journey is important
Its going to be similar with Wegovy - nausea, constipation, diarrhoea, and sometimes vomiting, particularly in the early weeks or after a dose increase
Doping detection and metabolism
If the medication is approved, the insurance coverage determination will dictate the level of coverage for the medication
